YOKNEAM, Israel–(BUSINESS WIRE)–Rapid Medical, a company focused on the development of responsive, adjustable neurovascular devices, announced today that Daniel Levangie has been appointed to its Board of Directors.
“We are thrilled to welcome Dan. Dan brings vast commercial experience, a deep perspective, and proven capabilities to our Board of Directors. His expertise will be invaluable and will complement the skills of our existing board members as we continue to grow and scale our company. I look forward to working with Dan,” said Dr. Shimon Eckhouse, the Chairman of Rapid Medical’s board.
Mr. Levangie is the Chairman, CEO and co-founder of Cerevasc, Inc., as well as the co-founder and Managing Partner of ATON Partners. In addition, he is a member of the Board of Directors of Exact Sciences, Inc. and Renovia, Inc. His long-term interest in the stroke treatment market started during his tenure as the Chairman of ev3 prior to its acquisition by Covidien.
“I am excited to join such a dynamic and mission-driven company,” said Dan. “Rapid Medical’s technology is a game-changer in neurovascular intervention. Through its innovative technology, its devices are fully adjustable in the brain. This means the devices are equipped to handle a broader range of patient anatomies and situations. I am looking forward to the opportunity to build a strong business with a significant impact on the lives of stroke patients.”
About Rapid Medical
Rapid Medical develops premier responsive interventional devices for endovascular diseases such as ischemic and hemorrhagic stroke. Utilizing novel manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the intravascular environment and have greater control over procedural outcomes. TIGERTRIEVER™ 17 and 21, COMANECI™ and COLUMBUS™/DRIVEWIRE are CE marked and FDA cleared. TIGERTRIEVER™ 13 and XL are also CE marked. More information is available at www.rapid-medical.com.